Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity – Percheron Therapeutics Limited ABN – 41 095 060 745 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Ben Gil Price Date of last notice 2 October 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) Not applicable Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 25 November 2024 No. of securities held prior to change Fully paid ordinary shares 999,805 Unquoted options 200,000 exercisable at 18.5c per option on or before 18 March 2025. Class 800,000 exercisable at 27c per option on or before 18 March 2025. Unquoted options Number acquired 3,000,000 Number disposed Value/Consideration Nil $0.063 per option Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Fully paid ordinary shares 999,805 No. of securities held after change Unquoted options 200,000 exercisable at 18.5c per option on or before 18 March 2025. 800,000 exercisable at 27c per option on or before 18 March 2025. 3,000,000 exercisable at 8.3c per option on or before 4 July 2029 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Options issued pursuant to Resolution 4 as approved by the shareholders at the 2024 Percheron Therapeutics Annual General Meeting held on 21 November 2024. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Not applicable Nature of interest Not applicable Name of registered holder (if issued securities) Not applicable Date of change Not applicable No. and class of securities to which Not applicable interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Not applicable Interest disposed Not applicable Value/Consideration Not applicable Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Not applicable + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the Not applicable trade to proceed during this period? If prior written clearance was provided, on what date was Not applicable this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3